BioCrossroads launches second seed fund
BioCrossroads Inc. has raised an $8.25 million seed fund in its second attempt to help startup life sciences companies grow to the point where they can attract venture capital or a corporate funder.
BioCrossroads Inc. has raised an $8.25 million seed fund in its second attempt to help startup life sciences companies grow to the point where they can attract venture capital or a corporate funder.
Health insurance customers in Indiana will get an estimated $16.5 million in rebates this year, but the average amount received per person will be less than the national average and less than 3 percent of the total cost of coverage.
A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
More than 3 million health insurance policyholders and thousands of employers will share $1.3 billion in rebates this year, thanks to health care reforms, a research group said Thursday. Indianapolis-based WellPoint Inc. is expected to return $94 million.
Indiana-based orthopedic implant maker Zimmer Holdings Inc. on Thursday reported a fractional increase in first-quarter profit on higher sales in all global regions, particularly the Asia Pacific.
David Karandos failed to make fine payments due March 1 and April 1, and Securities Commissioner Chris Naylor has ordered him to appear at a May hearing to make the case why “additional consequences” aren’t warranted.
Indianapolis-based WellPoint Inc. sees a $100 billion market in the states it serves to provide managed care for poor, elderly patients in the Medicare and Medicaid programs.
RepuCare said the additional jobs will support growth in its staffing business as well as its business providing on-site health care to employers.
Lilly’s quarterly sales and profit fell due to lost patent protection on Gemzar and Zyprexa. But sales of antidepressant Cymbalta, blood thinner Effient, animal health products and sales in China grew by 20 percent or more.
The Indianapolis-based health insurer posted first-quarter earnings of $857 million, down from $927 million in the same period a year ago.
Indiana University Health announced Tuesday that it will give $75 million in additional funding over the next five years to ramp up research at the Indiana University School of Medicine and launch more clinical trials around the state.
The Indianapolis-based not-for-profit network of health care centers said J. Cornelius Brown, who arrives from Swope Health Services in Kansas City, Mo., will replace the retiring Booker Thomas.
A group of 123 doctors, nurse practitioners and physician assistants have formed the Eskenazi Medical Group in order to focus on maximizing patient care and related bonus payments at Wishard Health Services.
More people have jobs and yet the use of health care remains stagnant—which should drive nice profits when WellPoint Inc. reports first-quarter earnings on Wednesday. The trends even have some wondering if consumer-driven health plans are finally starting to make a real difference in Americans’ health care spending habits.
The charge stems from a legal dispute involving changes in some life-insurance policies sold by subsidiary Conseco Life Insurance Co.
Participation in Saturday's Central Indiana Race for the Cure in downtown Indianapolis dropped about 28 percent from last year's event, to 27,126. Last year's race, held on a cold, rainy day, drew 37,450 people.
Seventy-two employees will lose their jobs when the 32-bed long-term-care facility shuts down on June 17. The company that operates the hospital did not provide a reason for the closing.
IBM’s supercomputer Watson is already a “Jeopardy!” champion. Now, three doctors in Indianapolis are trying to teach it how to treat cancer.
The $38 million Lyles-Porter Hall will house numerous health programs. Purdue also is planning a $25 million Drug Discovery Building that will bring together pharmaceutical researchers from throughout the school.
The proposal garnered support from the owners of 62 percent of Eli Lilly’s outstanding shares. To pass, the proposal needed approval from the owners of 80 percent of Lilly’s shares.